DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for uterine neoplasm — screening already-approved drugs against its 23-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleUterine neoplasm maps to a 23-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for uterine neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
endothelial PAS domain protein 1 (EPAS1) — EPAS1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet furan-2-ylmethyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3H82 · 1.5 Å · ligand N-(furan-2-ylmethyl)-2-nitro-4-(trifluoromethyl)aniline (020). Experimental structure, not a prediction.
What the evidence adds up to
Exome sequencing of 18 uterine leiomyomas from 17 patients identified tumour-specific mutations in the MED12 gene in 10 cases, and analysis of 207 additional tumours brought the total to 159 of 225 tumours (70%) from 80 patients carrying MED12 alterations, all confined to exon 2. This points to a recurrent genetic driver in benign fibroids, but the functional consequences of these mutations for the Mediator complex, a 26-subunit transcriptional regulator, were not established in the study. No therapeutic implication was drawn from this finding.
A 2008 literature review of medical therapy for uterine myomas concluded that many drugs are available in routine clinical practice and some are under investigation, but it provided no efficacy data, no drug names, and no comparative outcomes. A 2019 review on the etiopathogenesis of uterine fibroids describes them as monoclonal, hormone-sensitive neoplasms and invokes clonal expansion with neoangiogenesis as a core mechanism, while explicitly stating that pathogenesis remains complex and not fully understood. Neither review offers a concrete treatment recommendation backed by trial results.
For malignant uterine mesenchymal tumours, a 2024 narrative review notes that molecular data have accumulated to characterise these neoplasms, but it is a pathology and genetics update, not a clinical trial report. For uterine carcinosarcoma, a 2008 review states that surgery is primary, postoperative radiation may only improve loco-regional control, and adjuvant treatment has shifted from radiotherapy to chemotherapy; chemotherapy can extend life in advanced, persistent, or recurrent disease, but the effect "remains to be further enhanced." A 2022 case report describes a carcinosarcoma arising after pelvic irradiation for cervical cancer, and reviews the incidence, management, and prognosis of post-radiation uterine carcinosarcoma without providing survival statistics.
Two case reports document that severe adenomyosis can produce markedly elevated serum CA 125. One patient had a rising level from 150 to 391 u/ml with a 718 g uterus; another had a preoperative level above 6000 IU/ml. Both underwent hysterectomy with bilateral salpingo-oophorectomy, and in the second case the level returned to normal postoperatively. These are single-patient observations, not evidence for any drug, and they underscore the diagnostic ambiguity of CA 125 in benign uterine disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Science · 2011 · 662 citations
<i>MED12</i> , the <i>Mediator Complex Subunit 12</i> Gene, Is Mutated at High Frequency in Uterine Leiomyomas
AbstractUterine leiomyomas, or fibroids, are benign tumors that affect millions of women worldwide and that can cause considerable morbidity. To study the genetic basis of this tumor type, we examined 18 uterine leiomyomas derived from 17 different patients by exome sequencing and identified tumor-specific mutations in the mediator complex subunit 12 (MED12) gene in 10. Through analysis of 207 additional tumors, we determined that MED12 is altered in 70% (159 of 225) of tumors from a total of 80 patients. The Mediator complex is a 26-subunit transcriptional regulator that bridges DNA regulatory sequences to the RNA polymerase II initiation complex. All mutations resided in exon 2, suggesting that aberrant function of this region of MED12 contributes to tumorigenesis.
Expert Opinion on Emerging Drugs · 2008 · 60 citations
Uterine myoma: a condition amendable to medical therapy?
AbstractBACKGROUND: Uterine myomas are the most common benign tumors of the female reproductive tract. Of the different treatment methods available, medical therapy may be a less invasive choice. OBJECTIVE: To review the literature on medical treatments that are available or being developed for women with uterine myomas. METHODS: Literature review of articles pertaining to medical therapeutic strategies of uterine myomas. (Articles were searched by means of a computerized PubMed and Cochrane Library search with the following keywords: uterine myomas, leiomyomata, fibroids, and medical treatment.) RESULTS/CONCLUSION: At present, many drugs are available in routine clinical practice, some of which are under investigation. This review will explore the recent advances in medical treatment for the management of uterine myomas.
Uterine Mesenchymal Tumors: Updates on Pathology, Molecular Landscape, and Therapeutics
AbstractBackground: Mesenchymal uterine tumors are a diverse group of neoplasms with varying biological potential. Many of these neoplasms can have overlapping morphologic similarities, which, in some instances, render their diagnosis and categorization thorough histomorphologic examination inconclusive. In the last decade, an exponential amount of molecular data aiming to more accurately characterize and, consequently, treat these tumors have accumulated. Objective: The goal of this narrative review is to provide a pathologic review, a genetic update, and to know the new therapeutic avenues of primary uterine mesenchymal neoplasms.
International Journal of Surgery Case Reports · 2022 · 2 citations · open access
Radiotherapy-induced uterine cacinosarcoma
AbstractRadiation therapy is a very effective treatment modality for cervical cancer, but unfortunately, ionizing radiation is associated with many side effects, including secondary cancer formation. We report a case of carcinosarcoma of the uterus in a woman with a history of pelvic irradiation for cervical carcinoma. A review of the literature was performed to present the incidence, optimal management, and prognosis for post-radiation uterine carcinosarcoma.
Journal of Gynecologic Surgery · 2001 · 2 citations
Elevated Rising CA 125 with Adenomyosis
AbstractElevated serum CA 125 is useful in the management of ovarian cancer but has also been associated with several benign conditions. This is a report of a patient with an elevated, rising serum CA 125 level who was found to have a benign process. A 48-year-old woman with a 16-week-size uterus was thought to have leiomyomata uteri. Her serum CA 125 level was initially 150 u/ml; on repeat determination 10 weeks later, it was 391 u/ml. Laparotomy with bilateral salpingo-oophorectomy and hysterectomy revealed pathologic changes only in the uterus, the uterine weight being 718 g. Histologically, the lesion proved to be extensive adenomyosis. Severe uterine adenomyosis may be associated with both an elevated and a rising serum CA 125 level.
The Internet Journal of Gynecology and Obstetrics · 2009 · 1 citations
Adenomyosis With Extremely Elevated CA 125 Levels
AbstractRaised CA 125 levels have been shown to be associated with various etiologies, notably ovarian cancer and endometriosis. We report a case of adenomyosis in a 53 year-old woman who presented with menorrhagia. The uterus was enlarged and she had a preoperative CA 125 level of > 6000 IU/ml. A total abdominal hysterectomy and bilateral salpingoophorectomies was done with an intraoperative frozen section. It showed adenomyosis and paraffin sections of the specimen confirmed no malignancy. The extremely elevated CA 125 level returned to the normal range postoperatively.
AbstractCarcinosarcoma(CS)of the uterus is a rare class of malignant female pelvic neoplasms.The primary modality of therapy for uterine CS is surgery.Postoperative adjuvant radiation therapy may only improve loco-regional control.Standard adiuvant treatment of uterine CS has shifted from primarily loco-regional radiotherapy to chemotherapy.Potentially more effective adjuvant chemotherapy regimens will be investigated.Chemotherapy can extend life for patients with advanced,persistent,or recurrent uterine CS.However,effect of chemotherapy remains to be further enhanced.
Key words:
Uterus; Carcinosarcoma; Radiotherapy; Drug therapy
Bulletin of Science and Practice · 2019 · 0 citations · open access
Key Etiopathogenetic Features of Formation of Uterine Myoma
AbstractThe steady growth of proliferative diseases from year to year is becoming more and more medical and social importance, which is associated with their clinical manifestations and recurrent course, adversely affect the quality of life and the ability to work of women. Uterine fibroids are the most common benign neoplasm in women of reproductive age. This article discusses the key issues of the etiopathogenesis of uterine fibroids. Uterine fibroids are a monoclonal hormone-sensitive neoplasm and are the most common tumour of the reproductive organs of women. The pathogenesis and developmental mechanisms of uterine fibroids today are complex and not fully understood. Perhaps the underlying theory is the ‘clonal expansion of uterine fibroids’, it is the clonal expansion that initiates the processes of neoangiogenesis, activated by tumor growth. Although to this day there remain many controversial and unresolved issues.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works using Disease Ontology synonyms, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
